Evidence map›Paper›PMID 37238916›Full record

ReviewBiomedicines2023

Metallic Nanoparticles: Their Potential Role in Breast Cancer Immunotherapy via Trained Immunity Provocation.

Elham Zarenezhad, Manal Hadi Ghaffoori Kanaan, Sura Saad Abdollah, Mohammad Kazem Vakil, Mahrokh Marzi, Abdulbaset Mazarzaei, Abdolmajid Ghasemian

Abstract readReview
In one paragraph

Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Designing lysate-based hydrogels for on-demand therapy.Journal of pharmaceutical analysis · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elham ZarenezhadNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa 7461686688, Iran.ORCID 0000-0003-2805-1910
Manal Hadi Ghaffoori KanaanDepartment of Agriculture, Technical Institute of Suwaria, Middle Technical University, Baghdad 9768876516, Iraq.
Sura Saad AbdollahSuwaria Primary Health Care Sector, Wassit Health Office, Sharjah 9668866516, Iraq.
Mohammad Kazem VakilNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa 7461686688, Iran.
Mahrokh MarziNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa 7461686688, Iran.
Abdulbaset MazarzaeiDepartment of Immunology, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr 7618815676, Iran.
Abdolmajid GhasemianNoncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa 7461686688, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to drawbacks in the current common cancer therapies including surgery, chemotherapy and radiotherapy, the development of more reliable, low toxic, cost-effective and specific approaches such as immunotherapy is crucial. Breast cancer is among the leading causes of morbidity and mortality with a developed anticancer resistance. Accordingly, we attempted to uncover the efficacy of metallic nanoparticles (MNPs)-based breast cancer immunotherapy emphasizing trained immunity provocation or innate immunity adaptation. Due to the immunosuppressive nature of the tumor microenvironment (TME) and the poor infiltration of immune cells, the potentiation of an immune response or direct combat is a goal employing NPs as a burgeoning field. During the recent decades, the adaptation of the innate immunity responses against infectious diseases and cancer has been recognized. Although the data is in a scarcity with regard to a trained immunity function in breast cancer cells' elimination, this study introduced the potential of this arm of immunity adaptation using MNPs.

Indexed as

breast cancercancer therapydrug deliverynanoparticlestrained immunity

Identifiers

PMID37238916
PMCPMC10215451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.